Genentech
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · California, United States · 10K+ Employees
View Company Info for Free
Overview
Headquarters
1 Dna Way, South San Francisco, Californ...Phone Number
(877) 436-3683Website
www.gene.comRevenue
$2.5 BillionIndustry
About Genentech
Genentech, Inc. specializes in developing prescription medicines for the treatment of multiple sclerosis (MS), specifically targeting relapsing forms and primary progressive MS in adults. Their primary products, OCREVUS® (ocrelizumab) and OCREVUS ZUNOVO® (ocrelizumab & hyaluronidase-ocsq), offer both intravenous and subcutaneous administration options. The company aims to provide effective treatment solutions while also offering support services, financial assistance, and resources for patients living with MS. Genentech is committed to improving the quality of life for individuals affected by MS through innovative therapies and comprehensive care.Explore more
Genentech Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to Genentech
Compare insights from companies similar to Genentech, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$30.5B
10K+
Public
$296.3M
1987
Christopher IwataChief of Staff To the Executive Vice President of Human Resources
Genentech Tech Stack
A closer look at the technologies used by Genentech
Top Manufacturing Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Genentech
Sign Up For FreeTo access detailed company insights
Genentech, Inc. specializes in developing prescription medicines for the treatment of multiple sclerosis (MS), specifically targeting relapsing forms and primary progressive MS in adults. Their primary products, OCREVUS® (ocrelizumab) and OCREVUS ZUNOVO® (ocrelizumab & hyaluronidase-ocsq), offer both intravenous and subcutaneous administration opti... Read More
